Selling Buzz: Vertex Pharmaceuticals Incorporated [VRTX] Director Bhatia Sangeeta N. sells 621 shares of the company

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vertex Pharmaceuticals Incorporated shares valued at $173,116 were sold by Bhatia Sangeeta N. on Jul 29. At $278.77 per share, Bhatia Sangeeta N. sold 621 shares. The insider’s holdings dropped to 5,282 shares worth approximately $1.45 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, LEIDEN JEFFREY M sold 132,079 shares, netting a total of over 37,164,481 in proceeds. Following the sale of shares at $281.38 each, the insider now holds 2,423 shares.

Before that, ALTSHULER DAVID had sold 17,865 shares from its account. In a trade valued at $5,156,730, the EVP, Global Research and CSO traded Vertex Pharmaceuticals Incorporated shares for $288.65 each. Upon closing the transaction, the insider’s holdings decreased to 17,865 shares, worth approximately $9.92 million.

As published in their initiating research note from Cantor Fitzgerald on July 13, 2022, Vertex Pharmaceuticals Incorporated [VRTX] has been an Overweight and the price target has been revised to $365. This represents a 24.7% premium over Thursday’s closing price. Analysts at Maxim Group upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early June. As of May 23, 2022, SVB Leerink has initiated its “Mkt perform” rating for VRTX. Earlier on May 06, 2022, Robert W. Baird downgraded its rating. Their new recommendation was “a Neutral” for VRTX stock which previously was a “an Outperform”.

Analyzing VRTX’s Price Performance

On Thursday, Vertex Pharmaceuticals Incorporated [NASDAQ: VRTX] plunged -0.07% to $274.85. The stock’s lowest price that day was $272.93, but it reached a high of $278.1425 in the same session. During the last five days, there has been a drop of approximately -2.13%. Over the course of the year, Vertex Pharmaceuticals Incorporated shares have jumped approximately 25.16%. Shares of the company reached a 52-week high of $296.84 on 07/11/22 and a 52-week low of $214.66 on 01/03/22. A 50-day SMA is recorded $276.91, while a 200-day SMA reached $242.22. Nevertheless, trading volume fell to 2.01 million shares from 1.01 million shares the previous day.

Support And Resistance Levels for Vertex Pharmaceuticals Incorporated (VRTX)

According to the 24-hour chart, there is a support level at 272.47, which, if violated, would cause prices to drop to 270.10. In the upper region, resistance lies at 277.68. The next price resistance is at 280.52. RSI (Relative Strength Index) is 43.40 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -7.01, which suggests the price will decrease in the coming days. Percent R is at 86.59%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Vertex Pharmaceuticals Incorporated subject to short interest?

Stocks of Vertex Pharmaceuticals Incorporated saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.17 million shares to 3.59 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 3.42 million shares. A jump of 4.74% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.94 of the overall float, the days-to-cover ratio (short ratio) jumped to 1.94.

Which companies own the most shares of Vertex Pharmaceuticals Incorporated (VRTX)?

According to The Vanguard Group, Inc. filings, the company currently owns 19,458,715 shares, which is about 7.61% of the total VRTX shares outstanding. The investor’s shares have appreciated by 347,473 from its previous 13-F filing of 19111242.0 shares. With the completion of the sale transaction, BlackRock Fund Advisors’s stake is now worth $4,249,331,488. Capital Research & Management Co acquire a 9.94% interest valued at $3.57 billion while SSgA Funds Management, Inc. sold a -304,152 stake. A total of 3,740,586 shares of Vertex Pharmaceuticals Incorporated were sold by Fidelity Management & Research Co during the quarter, and 111,270 were bought by AllianceBernstein LP. In its current portfolio, Wellington Management Co. LLP holds 8,053,710 shares valued at $2.27 billion.

In terms of Vertex Pharmaceuticals Incorporated share price expectations, FactSet research, analysts set an average price target of $300.79 in the next 12 months, up nearly 9.99% from the previous closing price of $275.03. Analysts anticipate Vertex Pharmaceuticals Incorporated stock to reach $368.00 by 2022, with the lowest price target being $240.00. In spite of this, 29 analysts ranked Vertex Pharmaceuticals Incorporated stock as an Overweight at the end of 2022. On May 03, 2022, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and upgraded coverage with a $250.

LEAVE A REPLY

Please enter your comment!
Please enter your name here